Livestock health: Virbac launches TENOTRYLTM (enrofloxacin) injectable solution in the USA and increases its range of products

Westlake, TX / Wilmington, NC – July 11th, 2022

We continue to increase our footprint in the livestock market and are proud to announce the launch of TENOTRYLTM (enrofloxacin) injectable solution for use in cattle and swine. Our product was approved by the FDA on March 28th and will be available to those who care for animals beginning in July. TENOTRYLTM (enrofloxacin) injectable solution comes in 100, 250 and 500 ml vials.

This launch is the third product brought to the Livestock Health market by Virbac over the past six months. It demonstrates our strong commitment to propose to veterinarians and their customers, cattle and swine producers, a strong bench of new alternatives to improve the health of livestock and eventually their profitability.

Launching 3 products over the past 6 months is the best proof of our commitment to sustainably grow our offerings in the livestock health sector and to continuously propose more solutions to take care of the health of these animals, even in a context of rising feed and energy costs.” said Fabrice Payot, Vice President – Livestock Health, Virbac North America.

Regarding distribution, we market our cattle products via our own direct sales force; whereas for swine, we are partnering with Pharmgate. Under this arrangement, Pharmgate, with a very robust sales and technical services division, represents Virbac to swine veterinarians and producers across the USA.

The partnership with Virbac is working well and it is always great to see the range growing. The three new products naturally complement the Pharmgate range and we foresee more synergies and health programs to be developed in the near future.” said Dr. Chad Smith, incoming Vice President, Global Sales & Marketing at Pharmgate Animal Health.

Focusing on animal health, from the beginning
At Virbac, we provide innovative solutions to veterinarians, farmers and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products and services enables us to diagnose, prevent and treat the majority of pathologies. Every day, we are committed to improving animals’ quality of life and to shaping together the future of animal health.

Pharmgate Animal Health LLC is the joint venture between Pharmgate LLC, the majority-owned U.S. subsidiary of Jinhe Biotechnology Co., Ltd., P. R. China, the world leader in the production of chlortetracycline feed grade, chlortetracycline hydrochloride, and other animal health compounds and ECO Animal Health, London U.K., a leader in the development, registration and marketing of pharmaceutical products for global animal health markets including Aivlosin®, as well as a range of branded generic animal health therapeutic products.